Volitionrx Ltd SEC filings VNRX
Volitionrx Ltd has 1,004 filings in SEC EDGAR's recent list, going back to Aug 27, 2013. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (material agreement, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Jun 2, 2026 | Jul 17, 2026 |
| PRE 14A | Preliminary proxy statement | May 13, 2026 | May 12, 2026 |
| DEF 14A | Proxy statement | Feb 11, 2026 | Feb 10, 2026 |
| PRE 14A | Preliminary proxy statement | Jan 26, 2026 | Jan 22, 2026 |
| DEF 14A | Proxy statement | Apr 29, 2025 | Apr 24, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2025 | Jun 18, 2025 |
| DEF 14A | Proxy statement | May 13, 2024 | Jul 2, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 26, 2024 | Jul 2, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Apr 28, 2023 |
| DEF 14A | Proxy statement | Apr 28, 2022 | Apr 28, 2022 |
| DEF 14A | Proxy statement | Apr 29, 2021 | Apr 29, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2021 | Apr 2, 2021 |
| DEFA14A | Additional proxy material | Jun 17, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Apr 29, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2020 | Apr 1, 2020 |
| DEF 14A | Proxy statement | Apr 29, 2019 | Apr 29, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 29, 2019 | Mar 28, 2019 |
| DEF 14A | Proxy statement | Jul 20, 2018 | Jul 16, 2018 |
| DEF 14A | Proxy statement | Jul 24, 2017 | Jul 20, 2017 |
| DEF 14A | Proxy statement | Aug 22, 2016 | Aug 19, 2016 |
| PRE 14A | Preliminary proxy statement | Aug 5, 2016 | Aug 3, 2016 |
| DEFA14A | Additional proxy material | Sep 18, 2015 | — |
| DEF 14A | Proxy statement | Sep 16, 2015 | Sep 14, 2015 |
| PRE 14A | Preliminary proxy statement | Aug 21, 2015 | Aug 20, 2015 |
| DEFA14A | Additional proxy material | Jun 20, 2014 | — |
| DEF 14A | Proxy statement | Jun 20, 2014 | Jun 20, 2014 |
| PRE 14A | Preliminary proxy statement | Jun 9, 2014 | Jun 6, 2014 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VNRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Henderson, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 93314
- Former names
- VOLITIONRX LTD (until Oct 27, 2026); STANDARD CAPITAL CORP (until Sep 29, 2011)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.